AN2 THERAPEUTICS INC
ANTXNASDAQ🏆 #3111 by market capEarnings Nov 5US Equity
$5.87▼ $0.04 (−0.68%)
🌅 Pre-market$5.87▲ 0.00%Regular close · extended-hours price shown1h—
24h▼ 0.7%
7d▲ 0.5%
14d▲ 17.4%
30d▲ 28.9%
1y▲ 456.4%
🏦Market Cap
$211M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
65
Fair
Trading Snapshot
- Day Range
- $5.78 – $5.98
- 52-Week Range
- $1.00 – $6.91
- Volume
- $3.28B
- Avg Volume
- $3.09B
- Shares Outstanding
- 36.0M
- Next Earnings
- Oct 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $23M
- Last Q Revenue
- $6M
- P/E Ratio
- -5.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.81
- Dividend Yield
- 0.00%
Why Investors Own ANTX
- ✓High-growth profile — revenue up +22.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 30% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$23M▲ +24.1% YoY
Gross Margin (TTM)
30.2%▲ +2.0% YoY
Operating Income (TTM)
$3M▲ +24.1% YoY
Free Cash Flow (TTM)
$2M▲ +24.1% YoY
About AN2 THERAPEUTICS INC
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
65/100
Analyst Ratings
ⓘConsensus
Buy
8 analysts
Strong Buy4
Buy3
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026